45.04
price down icon3.18%   -1.48
pre-market  Pre-market:  48.00   2.96   +6.57%
loading
Apogee Therapeutics Inc stock is traded at $45.04, with a volume of 334.24K. It is down -3.18% in the last 24 hours and down -15.86% over the past month. Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
See More
Previous Close:
$46.52
Open:
$46.4
24h Volume:
334.24K
Relative Volume:
0.85
Market Cap:
$2.62B
Revenue:
-
Net Income/Loss:
$-118.49M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-110.57M
1W Performance:
-14.68%
1M Performance:
-15.86%
6M Performance:
-14.08%
1Y Performance:
+149.94%
1-Day Range:
Value
$44.37
$46.70
1-Week Range:
Value
$44.37
$53.52
52-Week Range:
Value
$16.39
$72.29

Apogee Therapeutics Inc Stock (APGE) Company Profile

Name
Name
Apogee Therapeutics Inc
Name
Phone
650-394-5230
Name
Address
221 CRESCENT ST., WALTHAM
Name
Employee
91
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
APGE's Discussions on Twitter

Compare APGE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
APGE 45.04 2.62B 0 -118.49M -110.57M 0.00
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades

Date Action Analyst Rating Change
May-10-24 Initiated BofA Securities Buy
Dec-20-23 Initiated BTIG Research Buy
Aug-08-23 Initiated Guggenheim Buy
Aug-08-23 Initiated Jefferies Buy
Aug-08-23 Initiated Stifel Buy
Aug-08-23 Initiated TD Cowen Outperform
Aug-08-23 Initiated Wedbush Outperform
View All

Apogee Therapeutics Inc Stock (APGE) Latest News

pulisher
Nov 19, 2024

Victory Capital Management Inc. Boosts Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Apogee Therapeutics Unveils First R&D Day: Spotlight on APG777 and Immunology Pipeline | APGE Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 15, 2024

Wedbush Cuts Earnings Estimates for Apogee Therapeutics - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Driehaus Capital Management LLC Acquires Shares in Apogee Therap - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Stifel maintains Buy on Apogee Therapeutics with $95 target - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Adjusts Stake in Apogee Therapeutics Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Apogee Therapeutics Highlights Pipeline Progress and Financials - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

APGEApogee Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Stifel maintains Buy on Apogee Therapeutics with $95 target By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Apogee Reports Promising APG777 Trial Data, $754M Cash Runway Through 2028 | APGE Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 10, 2024

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis - Seeking Alpha

Nov 10, 2024
pulisher
Nov 09, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 6,665 Shares - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Michael Thomas Henderson Sells 15,000 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Apogee Therapeutics Inc (APGE) Worth Considering For The Next Few Weeks - Stocks Register

Nov 09, 2024
pulisher
Nov 08, 2024

Insider Sale at Apogee Therapeutics Inc (APGE): Chief Medical Of - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Apogee Therapeutics chief medical officer sells shares worth $394,041 - Investing.com India

Nov 08, 2024
pulisher
Nov 08, 2024

Apogee Therapeutics CEO sells shares worth $888,320 - Investing.com

Nov 08, 2024
pulisher
Nov 08, 2024

Apogee Therapeutics chief medical officer sells shares worth $394,041 By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 06, 2024

(APGE) Proactive Strategies - Stock Traders Daily

Nov 06, 2024
pulisher
Nov 06, 2024

Apogee Therapeutics (NASDAQ:APGE) and Fennec Pharmaceuticals (NASDAQ:FENC) Financial Contrast - Defense World

Nov 06, 2024
pulisher
Nov 05, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World

Nov 05, 2024
pulisher
Nov 04, 2024

Apogee Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewswire

Nov 04, 2024
pulisher
Oct 31, 2024

Jade, another biotech spinout of Paragon, to merge with Aerovate - BioPharma Dive

Oct 31, 2024
pulisher
Oct 31, 2024

10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey

Oct 31, 2024
pulisher
Oct 27, 2024

(APGE) Investment Analysis and Advice - Stock Traders Daily

Oct 27, 2024
pulisher
Oct 25, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Wedbush Reiterates Outperform Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat

Oct 25, 2024
pulisher
Oct 24, 2024

Apogee Therapeutics Unveils Promising Phase 1 Trial Results - TipRanks

Oct 24, 2024
pulisher
Oct 24, 2024

Apogee Therapeutics Announces Results Up to 9 Months from - GlobeNewswire

Oct 24, 2024
pulisher
Oct 24, 2024

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel - The Bakersfield Californian

Oct 24, 2024
pulisher
Oct 24, 2024

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases - StockTitan

Oct 24, 2024
pulisher
Oct 20, 2024

Waypoint Capital Advisors LLC Invests $36.84 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

Oct 20, 2024
pulisher
Oct 18, 2024

Apogee Therapeutics (NASDAQ:APGE) Trading Down 4.1%Here's What Happened - MarketBeat

Oct 18, 2024
pulisher
Oct 16, 2024

(APGE) Technical Pivots with Risk Controls - Stock Traders Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

11,535 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by AQR Capital Management LLC - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Down 11.7% in September - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

Millennium Management LLC Lowers Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

Oct 14, 2024
pulisher
Oct 09, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by The Manufacturers Life Insurance Company - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Analyzing Apogee Therapeutics Inc. (APGE) After Recent Trading Activity - Knox Daily

Oct 08, 2024
pulisher
Oct 08, 2024

Ratio Examination: Apogee Therapeutics Inc. (APGE)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 08, 2024
pulisher
Oct 07, 2024

Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now - Insider Monkey

Oct 07, 2024
pulisher
Oct 05, 2024

Squarepoint Ops LLC Purchases 25,829 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

Oct 05, 2024
pulisher
Oct 05, 2024

Apogee Therapeutics executive sells over $370k in company stock - Investing.com India

Oct 05, 2024
pulisher
Oct 05, 2024

Apogee Therapeutics Inc CEO Michael Henderson Sells 40,000 Shares - GuruFocus.com

Oct 05, 2024
pulisher
Oct 04, 2024

Carl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Apogee Therapeutics CEO sells over $2.2 million in company stock By Investing.com - Investing.com Canada

Oct 04, 2024

Apogee Therapeutics Inc Stock (APGE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):